Warts and all: Reviewing an archetype

During my visit to HIMSS12 in February, I finally met Jerry Fahrni (@JFahrni) face to face – a pharmacist and Twitter colleague I’d had 140 character conversations over some years.

We’d also talked on Skype once about some of the clinical archetypes some time ago, and during our HIMSS conversation I managed to persuade him to take a look at the openEHR community’s Adverse Reaction archetype and participate in the community review.

He did, and at my further request he has put ink to blog and has recorded his experience as a newbie reviewer so that others might have some sense of what completing an archetype review entails, warts and all.

Jerry’s review, reproduced here:

…According to good ol’ Merriam-Webster an archetype is “the original pattern or model of which all things of the same type are representations or copies: also : a perfect example“. Simple enough, but still too vague for my brain so I went in search of a better explanation which I found at Heather’s blog – Archetypical.

According to the Archetypical site ”openEHR archetypes are computable definitions created by the clinical domain experts for each single discrete clinical concept – a maximal (rather than minimum) data-set designed for all use-cases and all stakeholders. For example, one archetype can describe all data, methods and situations required to capture a blood sugar measurement from a glucometer at home, during a clinical consultation, or when having a glucose tolerance test or challenge at the laboratory. Other archetypes enable us to record the details about a diagnosis or to order a medication. Each archetype is built to a ‘design once, re-use over and over again’ principle and, most important, the archetype outputs are structured and fully computable representations of the health information. They can be linked to clinical terminologies such as SNOMED-CT, allowing clinicians to document the health information unambiguously to support direct patient care. The maximal data-set notion underpinning archetypes ensures that data conforming to an archetype can be re-used in all related use-cases – from direct provision of clinical care through to a range of secondary uses.” That gave me a better understanding of what they were trying to do.

Anyway, when Heather asked me to review the Adverse Reaction archetype I was a little hesitant. The projects I’m asked to be involved with are typically much smaller in scale. This was something different and I felt a little intimidated. My gut reaction was to politely decline, but when someone asks you to do something face to face it makes excusing yourself for some lame reason a lot harder. So I agreed with more than a bit of trepidation.

The openEHR project utilizes a system called the Clinical Knowledge Manager (CKM). In the most basic terms, the CKM is an online content management system for all the archetypes being designed by the openEHR project, and it’s impressive. A more in depth description can be found here.

Logging into the system was simple. The email invitation I received to review the Adverse Reaction Archetype contained a link that took me to the exact location I was supposed to be. From there things got a bit more complicated. The CKM is easy enough to navigate, but the amount of information and navigational elements within the system is staggering. It took me a while to figure out exactly what I was supposed to do. Once I figured it out I was able to quickly go through the archetype, read what other comments people had made and make a couple of minor notes myself. One thing I could never completely figure out was how to save my work in the middle and continue later. Sounds simple enough, but for whatever reason it just wasn’t obvious to me. I ended up powering through my “review” in one extended session because I was afraid I’d lose my place.
The archetype itself was impressive. It’s clear from the information and detail that people have spent a lot of time and effort developing the adverse reaction archetype. There’s no question that a lot of great minds had been involved in this work. The definition made sense as did the data that was being collected and presented. The archetype offered flexibility for information gathering that included the simplest form of adverse reaction to complex re-exposure and absolute contraindication notation (this is sorely missing in many systems I’ve used over my career). Overall I had little insight to offer during the review, only a couple of minor comments.

I’d say the entire process was pretty straightforward with some minor complications. Like everything else I’m sure the process would get easier over time and multiple uses.

Thanks Jerry. Your independent and honest opinion is much valued.
Perhaps next time… !! (Just joking)

Desmond Tutu on the global challenge of eHealth

The highlight of this week’s HealtheNation conference was not the Health Minister or any of the other speakers, but a modest pre-recorded video presentation by Archbishop Emeritus Desmond Tutu.

As a Global eHealth ambassador for the International Society for Telemedicine and eHealth he spoke with credibility and a passion for realigning the imbalance in health care delivery using eHealth. Nothing particularly world shattering or new, but even I could put aside my natural scepticism and feel a little inspired – I liked that & thought I’d share it :)

Apologies for my hand-held phone recording…

CIMI… one of many crossroads

Grahame Grieve posted CIMI at the Crossroads recently. I can’t disagree with a lot of the content, but maybe I’m a bit more of an optimist as I draw some slightly different conclusions.

Grahame is totally right about what it has achieved so far:

  • a significant membership roll that has never been achieved before
  • a significant agreement of an initial approach to clinical models – a primary formalism of ADL 1.5/AOM with a commitment to support transformation to isosemantic UML models in a spirit of inclusivity and harmonisation.

And as he points out, the notion that the modelling methodology was chosen independently of the Reference Model is somewhat disconcerting.

“…the decision to choose ADL/AOM as the methodology, while deferring the choice of reference model. While I understood the political reality of this decision, choosing an existing methodology (ADL/AOM) but not the openEHR reference model committed CIMI to building at least a new tooling chain, a new community, and possibly a new reference model.

The cost of this is high; so high that the opportunity created by the foundation of CIMI may likely founder if we see another attempt to reinvent the health IT wheel, yet again.

There are many opinions, and everyone at the CIMI table has their own bias, history, experience. Organisational and personal investment in each existing solutions are high. No one wants to throw away their efforts and ‘start again’; everyone wants their work to be the successful and sustained.

The CIMI community do need to make an objective decision if it is to move forward. It may not be result which wins a popularity contest. It is very likely that some members will walks away and keep working as they always have; maybe intending to return when a more mature solution is on offer.

In his paragraph on the pros and cons of openEHR, Grahame very eloquently states:

This is the first choice: pick the least worst established clinical modelling paradigm.

:)

“Least worst” – Thanks Grahame! You could turn that around: the ‘best’ available so far, where there is no perfect solution!

But it’s not a bad principle – to take the least worst and make it better!

The chair of the openEHR board, Sam Heard proposed the following to the openEHR community back in October 2011:

“If the CIMI group chooses to use ADL as the formalism then the openEHR community is prepared to explore the Foundation governance arrangements with the CIMI group and align the two efforts using the structures that are mutually agreed.

Changes to ADL and the openEHR Reference Model may be part of the process to meet the collective needs, and alignment of the shared RM and a reviewed RM for ISO 13606 would also be a major goal. ADL 1.5 would be submitted to ISO as part of this alignment.”

Seems sensible to me – start with a robust candidate and modify/enhance it to meet the collective needs. The latest version of the openEHR RM is clearly one candidate. It has evolved significantly from the 2005 version which forms the basis of ISO 13606. Given that ISO 13606 (parts 1-5) is due for revision this year, perhaps we have a great opportunity for harmonisation. The openEHR community is already starting to develop a proposal for the revision, but a greater achievement would be to align all of these efforts into a new 13606/openEHR/CIMI specification.

This is a difficult task that we are trying to solve. We know that because it has not been solved before.

This is definitely not the first crossroad that CIMI has encountered – don’t underestimate the effort that has brought the group to this point – and it will definitely not be the last. What will determine success is keeping the end goal front and centre in CIMI’s decision-making; cutting ruthlessly through the political and personal agendas; putting pragmatism ahead of perfection; and a willingness to compromise in order to move forward.

It may not be possible. It could be a hell of a ride. I still think it has the potential make a hell of a difference.